

**PB 112 of 2024**

**National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024   
(No. 10)**

*National Health Act 1953*

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 30 October 2024

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Pharmaceutical benefits—early supply) Instrument 2015   
(PB 120 of 2015). 2

1 Name

1. This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 10)*.
2. This instrument may also be cited as PB 112 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 November 2024* | *1 November 2024* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)*

1. Schedule 1, after entry for Dapagliflozin with metformin in the form Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dapagliflozin with sitagliptin | Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate) | 20 | 28 | 5 |  |

1. Schedule 1, entry for Estradiol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estradiol | Tablet 2 mg | 20 | 56 | 2 |  |
| Tablet containing estradiol valerate 1 mg | 20 | 56 | 2 |  |
| Tablet containing estradiol valerate 2 mg | 20 | 56 | 2 |  |
| Transdermal gel 500 micrograms in 0.5 g sachet, 28 | 20 | 1 | 5 |  |
| Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | 20 | 1 | 5 |  |
| Transdermal patches 390 micrograms, 8 | 20 | 1 | 5 |  |
| Transdermal patches 585 micrograms, 8 | 20 | 1 | 5 |  |
| Transdermal patches 585 micrograms, 24 (S19A) | 20 | 1 | 1 |  |
| Transdermal patches 750 micrograms (as hemihydrate), 8 | 20 | 1 | 5 |  |
| Transdermal patches 780 micrograms, 8 | 20 | 1 | 5 |  |
| Transdermal patches 780 micrograms, 24 (S19A) | 20 | 1 | 1 |  |
| Transdermal patches 1.17 mg, 8 | 20 | 1 | 5 |  |
| Transdermal patches 1.17 mg, 24 (S19A) | 20 | 1 | 1 |  |
| Transdermal patches 1.5 mg (as hemihydrate), 8 | 20 | 1 | 5 |  |
| Transdermal patches 1.56 mg, 8 | 20 | 1 | 5 |  |
| Transdermal patches 1.56 mg, 24 (S19A) | 20 | 1 | 1 |  |
| Transdermal patches 3 mg (as hemihydrate), 8 | 20 | 1 | 5 |  |

1. Schedule 1, after entry for Methotrexate in the form Injection 25 mg in 0.5 mL pre-filled syringe

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Tablet 10 mg | 20 | 10 | 5 |  |

1. Schedule 1, omit entry for Ribavirin
2. Schedule 1, entry for Risankizumab

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Injection 75 mg in 0.83 mL pre‑filled syringe | 20 | 2 | 1 |  |

1. Schedule 2, after entry for Dapagliflozin with metformin in the form Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dapagliflozin with sitagliptin | Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate) | 50 | 56 | 5 |  |

1. Schedule 2, after entry Estradiol in the form Tablet containing estradiol valerate 2 mg

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Transdermal gel 500 micrograms in 0.5 g sachet, 28 | 50 | 2 | 5 |  |